Lexicon Pharmaceuticals Inc Stock Price, News & Analysis

Lexicon Pharmaceuticals (NASDAQ: LXRX) presented the design of its SONATA-HCM Phase 3 clinical trial at Heart Failure 2025, evaluating sotagliflozin for both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). The study is actively enrolling 500 patients across 20 countries, with all sites expected to be operational by September 2025.

The trial aims to assess sotagliflozin's efficacy on symptoms, function, and patient-reported outcomes in HCM patients. The primary endpoint measures symptom improvement using the Kansas City Cardiomyopathy Questionnaire at week 26. Recent evidence published in The Lancet (February 2025) suggests sotagliflozin's dual SGLT1 and SGLT2 inhibition reduces major adverse cardiovascular events.

If successful, the study could support a supplemental new drug application (sNDA) for sotagliflozin in both HCM types, addressing a significant unmet need, particularly for non-obstructive HCM where no approved therapies exist.

Lexicon Pharmaceuticals (LXRX) reported Q1 2025 financial results and business updates. The company secured an exclusive license agreement with Novo Nordisk for LX9851, potentially worth up to $1 billion in payments. Their Phase 2b PROGRESS study confirmed 10 mg pilavapadin as the optimal dose for Phase 3 development in diabetic peripheral neuropathic pain. Q1 financial results showed revenues of $1.3 million, R&D expenses of $15.3 million, and reduced SG&A expenses to $11.6 million. Net loss improved to $25.3 million ($0.07 per share) from $48.4 million in Q1 2024. The company ended Q1 with $194.8 million in cash and investments. Lexicon is advancing multiple pipeline programs, including sotagliflozin for hypertrophic cardiomyopathy in the SONATA-HCM Phase 3 study.

Lexicon Pharmaceuticals (NASDAQ: LXRX) announced its participation in the upcoming 3rd Annual H.C. Wainwright BioConnect Investor Conference. The company's management will engage in a fireside chat scheduled for Tuesday, May 20, at 9:30 a.m. ET at the Nasdaq World Headquarters in New York City. Investors and interested parties can access both the live presentation and its replay through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Lexicon Pharmaceuticals (NASDAQ: LXRX) has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) on the same day, where management will discuss the quarterly results and provide a business update. Interested participants can access the webcast through the Events page on Lexicon's investor website, while those wishing to ask questions during the call can register to receive dial-in information. An archived version of the webcast will be made available on the company's website for later viewing.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming participation in the 24th Annual Needham Virtual Healthcare Conference 2025. The company's management will deliver a presentation on Wednesday, April 9, at 8:00 a.m. ET.

Investors and interested parties can access both the live event and a replay of the presentation through the Events section of Lexicon's investor relations website at https://investors.lexpharma.com/.

Lexicon Pharmaceuticals (LXRX) has entered into an exclusive worldwide license agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin drug candidate targeting obesity and metabolic disorders. The deal includes potential payments of up to $1 billion, with $75 million in upfront and near-term milestone payments.

LX9851 is a selective oral small molecule inhibitor of ACSL5, targeting fat accumulation and energy balance regulation. Preclinical data from Obesity Week 2024 demonstrated that LX9851, when combined with semaglutide, significantly reduced weight, food intake, and fat mass compared to semaglutide alone. The drug also showed positive effects on liver steatosis and mitigated weight regain after semaglutide discontinuation.

Under the agreement, Novo Nordisk will handle IND filing, development, manufacturing, and commercialization, while Lexicon completes IND-enabling activities. Lexicon will receive tiered royalties on net sales in addition to milestone payments.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has announced its upcoming participation in the Leerink Partners Global Healthcare Conference 2025 in Miami. The company's management will engage in a fireside chat scheduled for Wednesday, March 12, at 10:00 a.m. ET. Both the live presentation and a subsequent replay will be made available to interested parties through the Events section of Lexicon's investor relations website at investors.lexpharma.com.

Lexicon Pharmaceuticals (LXRX) reported its Q4 and full-year 2024 financial results, highlighting progress in its R&D pipeline. The company's Q4 2024 revenues increased to $26.6 million from $0.7 million in Q4 2023, including a $25.0 million upfront payment from the Viatris INPEFA licensing agreement.

Key developments include positive topline results from the PROGRESS Phase 2b study of pilavapadin (LX9211) for diabetic peripheral neuropathic pain, with the 10 mg dose advancing to Phase 3 development in 2025. The company is also progressing with LX9851 for obesity and continuing enrollment in the SONATA HCM Phase 3 trial for sotagliflozin.

Financial highlights show Q4 2024 net loss of $33.8 million ($0.09 per share), compared to $49.8 million ($0.20 per share) in Q4 2023. R&D expenses increased to $26.7 million, while SG&A expenses slightly decreased to $32.3 million. The company ended 2024 with $238.0 million in cash and short-term investments.

Lexicon Pharmaceuticals (Nasdaq: LXRX) has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, March 6, 2025, after market close. The company will host a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) on the same day to discuss the financial performance and provide a business update.

Investors can access the conference call through the Events page on Lexicon's investor website. Those interested in asking questions during the call can register to receive dial-in information and a unique PIN. An archived version of the webcast will be available for later viewing on the company's website.